PMV Pharmaceuticals
A Doylestown, Penn-based developer of p53-targeted small molecule drugs for the treatment of cancer.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (597 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
PMV Pharmaceuticals, Inc. is a pioneering biotechnology company focused on developing innovative treatments for cancer. The company specializes in creating first-in-class p53 regulators, targeting the most commonly mutated protein in human cancers. By harnessing over three decades of p53 biology, PMV Pharma combines a unique biological understanding with a strong focus on pharmaceutical development.
PMV Pharma operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from various forms of cancer. The company's business model revolves around the research, development, and commercialization of novel cancer therapies. Revenue is generated through the successful development and eventual sale or licensing of their proprietary treatments.
The company is led by a team of industry and academic thought leaders who are dedicated to discovering new treatments for human diseases. This leadership team brings together extensive experience in both scientific research and pharmaceutical development, ensuring a robust approach to tackling cancer.
PMV Pharma's core mission is to harness the power of p53 to treat cancer, offering hope and potential cures to millions of patients worldwide. The company is headquartered in Cranbury, NJ, and continues to make significant strides in the field of oncology.
Keywords: p53 regulators, cancer treatment, biotechnology, pharmaceutical development, oncology, novel therapies, scientific research, cancer patients, innovative treatments, academic leaders.
